EIF3C

Eukaryotic translation initiation factor 3 subunit C · Q99613 · EIF3C on Sugi Atlas →

0 patent compounds predicted against EIF3C, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EIF3C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery PHASE2WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF3C binder may also engage these)

ProteinNameSimilarity
B5ME19 1.000 B5ME19 →
Q3SYW6 1.000 Q3SYW6 →
Q5RAT8 1.000 Q5RAT8 →
Q8R1B4 1.000 Q8R1B4 →
Q4QR58 1.000 Q4QR58 →
Q6P1V4 1.000 Q6P1V4 →
B5DFC8 1.000 B5DFC8 →
Q6PFQ2 1.000 Q6PFQ2 →
B4HMY3 1.000 B4HMY3 →
B4LNA1 1.000 B4LNA1 →
B4KN00 1.000 B4KN00 →
Q28Z41 1.000 Q28Z41 →
B3NML0 1.000 B3NML0 →
B4P562 1.000 B4P562 →
B3MIF1 1.000 B3MIF1 →
A1ZAX1 1.000 A1ZAX1 →
B4GIB1 1.000 B4GIB1 →
O02328 1.000 O02328 →
B4MRZ8 1.000 B4MRZ8 →
Q17Q06 0.998 Q17Q06 →
B4J789 0.998 B4J789 →
B0W0S3 0.997 B0W0S3 →
O14164 0.997 O14164 →
Q7PMU8 0.997 Q7PMU8 →
A8WWU0 0.997 A8WWU0 →
A6S043 0.996 A6S043 →
Q2H731 0.995 Q2H731 →
A1C987 0.995 A1C987 →
Q4W9S8 0.993 Q4W9S8 →
Q6C855 0.993 Q6C855 →